Why Is The Price Of Anticancer Drugs So High?

- Aug 13, 2019-

The production of anticancer drugs costing about 100 yuan, but selling 10,000 days! The exaggeration in exaggeration is that the production cost of 900 yuan for the treatment of hepatitis C, Sovaldi, which was marketed in 2014, has been sold to 500,000! Over 500 times!

Cancer patients and their families are always worried about the cost of taking medicine. Is it deliberately preventing patients from getting medicine? Is it the country to let go? What kind of hiddenness is behind this?

Anti-cancer drugs are cheaper than thousands, expensive tens of thousands, saying that drugs are not exaggerated than gold, especially the original research drugs.

The original drug, which refers to the original new drug, was approved for screening after tens of thousands of compound layer screening and rigorous clinical trials. The research and development costs of the original research drugs are high, the risks are high, and the cycle is long (usually more than 10 years). It is necessary to invest enough manpower, financial resources and equipment.

With billions of dollars in spending, general pharmaceutical companies simply cannot afford it. Therefore, the cost of the original research drug is not in the raw materials and production, but in the research and development before the listing!

From "nothing" to "having"

The development of anticancer drugs is not just about getting a tablet to figure out the ingredients, but about blind people, not only to be able to draw the outline and details of the elephant, but also to figure out how to find the elephant and grab him. Feed what it eats, how to eat it, how to digest it, whether it can grow healthily, how to get along well, whether it is harmful to the body, side effects, etc. When you thoroughly study how to develop an elephant, you can bring an elephant out. At this time, the elephant you meet with is not simply the price that can be measured by the meat of a few hundred pounds of elephant.

The research team of pharmaceutical companies needs great human support, and they are searching and screening from the vast quantities of materials in the day and night to study whether the drug composition, mechanism of action, effect is significant, toxicity to the human body, side effects and so on.

A group of blind people to touch the image, but also to touch at least 10 years, this time spent a lot of time, energy and endurance, can imagine how high the cost. Another point, the need to invest in it is high-education, high-income elite talent, the cost of team members for several years is also very high.

High failure rate

The key point is that with such a long period of time and so much manpower and material resources, the rate of research and development failures in the end is still very high, and the smooth development of new drugs is far from being as simple as listening. However, the pharmaceutical companies have to pay the “touching” team, and they have been paying for so many years, even if they did not touch it. Also consider the opportunity cost.

Large pharmaceutical companies have more money, and the amount is not unlimited. Therefore, if a limited amount of money is invested in touching this image, it is necessary to consider abandoning other elephant groups and losing the possibility of another original drug.

Patent protection period

Then, even if you have to pay so much time, financial resources, material resources, and manpower, it is very difficult to succeed. Why are pharmaceutical companies willing to engage in the original research drugs? Because there is a patent protection period, that is, it can monopolize the market within a certain period of time, and set a high price for the drug, so as to recover the cost of developing the drug.

Although from the perspective of human feelings, drugs as a special commodity, and the equal sign with money always feel unappealing. However, after all, pharmaceutical companies are not public welfare undertakings and commercial companies. Therefore, in order to achieve sustainable development and the significance of the existence of the company, it is necessary to achieve profitability, which has caused the inevitable high price of anticancer drugs.

The patent protection period is generally 20 years, but it is not calculated from the time the drug is marketed, but has been started since the early entry into clinical trials. Therefore, when the drug is actually listed, the patent protection period has basically passed most of the time. During the remaining protection period, the pharmaceutical company will cherish this limited “good spring” and set the drug price as high as possible for recycling. Cost and profitability. Because once the patent period has passed, various generic drugs will emerge in an endless stream, and the price of the original drug will be lowered in a cliff-like manner.

The so-called generic drug refers to the fact that it is not directly developed by the drug factory and directly produced according to the original drug. The average price is only about 10% to 15% of the original drug. The US FDA stipulates that generic drugs must be identical to the generic drugs they use in terms of "active ingredients, dosage, safety, efficacy, effects (including side effects), and the disease being targeted."

Benefit-driven innovation

From a certain point of view, it can even be said that the original drug must be more expensive in order to maintain the power of innovation and research and development of large pharmaceutical companies. For example, when the Ebola virus was only found in Africa in the early days, there was no medicine or vaccine, and it was largely because the drug companies felt that they had no money to make. By the time of the most concentrated virus outbreak in 2014, it was introduced into Europe and the American continent, which attracted the attention of large pharmaceutical companies. In just one year, several companies have researched Ebola vaccines and drugs. Healing the monkey model, and even the clinical effect is very good.

Therefore, the introduction of innovative new drugs must be driven by economic interests. This is also a good thing for the patient.

After successful development

Mass production, environmental protection, government taxation, as well as transportation, storage, loss, etc., should also consider the promotion of post-marketing, such as giving doctors a presentation, which are the reasons for increased costs and high prices.